REFERENCES
1. Giugliani R, Niu DM, Ramaswami U, et al. A 15-year perspective of the Fabry outcome survey. J Inborn Errors Metab Screen. 2016;4:232640981666629.
2. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276:1163-7.
3. Mehta A, Beck M, Linhart A, Sunder-Plassmann G, Widmer U. History of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.
4. Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet. 1994;3:1795-9.
5. Terryn W, Vanholder R, Hemelsoet D, et al. Questioning the pathogenic role of the GLA p.Ala143Thr “mutation” in Fabry disease: implications for screening studies and ERT. JIMD Rep. 2013;8:101-8.
6. Hsu TR, Chang FP, Chu TH, et al. Correlations between endomyocardial biopsies and cardiac manifestations in Taiwanese patients with the Chinese hotspot IVS4+919G>A mutation: data from the fabry outcome survey. Int J Mol Sci. 2017;18:119.
7. Liu H, Perrin A, Hsu T, et al. Age at first cardiac symptoms in Fabry disease: association with a Chinese hotspot Fabry mutation (IVS4+919G>A), classical Fabry mutations, and sex in a Taiwanese population from the Fabry outcome survey (FOS). JIMD Rep. 2015;22:107-13.
8. Stenson PD, Mort M, Ball EV, et al. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136:665-77.
9. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest. 2004;34:236-42.
10. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769-75.
11. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750-60.
12. Politei JM, Solar B. Gastrointestinal involvement in Fabry disease. Rare Dis Orphan Drugs J. 2024;3:10.
13. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31-40.
14. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-54.
15. Lin HY, Chong KW, Hsu JH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009;2:450-6.
16. Germain DP, Levade T, Hachulla E, et al. Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease. Clin Genet. 2022;101:390-402.
17. Beck M, Cox TM. Comment: why are females with Fabry disease affected? Mol Genet Metab Rep. 2019;21:100529.
18. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743-9.
19. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16.
20. Schiffman R. Investigating Fabry disease - some lessons learned. Rare Dis Orphan Drugs J. 2024;3:4.
21. Hasholt L, Wandall A, Sørensen SA. Enzyme replacement in Fabry endothelial cells and fibroblasts: uptake experiments and electron microscopical studies. Clin Genet. 1988;33:360-71.
23. Hasholt L, Sørensen SA, Wandall A, Andersen EB, Arlien-Søborg P. A Fabry's disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. J Med Genet. 1990;27:303-6.
24. Andersen MV, Dahl H, Fledelius H, Nielsen NV. Central retinal artery occlusion in a patient with Fabry's disease documented by scanning laser ophthalmoscopy. Acta Ophthalmol. 1994;72:635-8.
25. Madsen KM, Hasholt L, Sørensen SA, Fermér ML, Dahl N. Two novel mutations (L32P) and (G85N) among five different missense mutations in six Danish families with Fabry's disease. Hum Mutat. 1995;5:277-8.
26. Madsen KM, Hasholt L, Sørensen SA, van Loo A, Vanholder R. The utility of single-strand conformation polymorphism (SSCP) analysis: results obtained in families with Fabry's disease. Scand J Clin Lab Invest. 1996;56:177-82.
27. Madsen KM, Hasholt L, Berger J, Sørensen SA. SSCP analysis of paraffin wax embedded tissues in a family with an atypical form of Fabry disease. Clin Mol Pathol. 1996;49:M310-2.
28. Rosenberg KM, Schiffmann R, Kaneski C, Brady RO, Sorensen SA, Hasholt L. Five novel mutations in fourteen patients with Fabry disease. Hum Mutat. 2000;15:207-8.
29. Jensen E. On the pathology of angiokeratoma corporis diffusum (Fabry). Acta Pathol Microbiol Scand. 1966;68:313-31.
30. Feldt-Rasmussen U, Rasmussen AK, Mersebach H, Rosenberg KM, Hasholt L, Sorensen SA. Fabry disease: a new challenge in endocrinology and metabolism? Eur J Endocrinol. 2002;146:741-2.
31. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539-48.
32. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404-7.
33. Jäger AC, Friis-Hansen L, Hansen TV, et al. Characteristics of the Danish families with multiple endocrine neoplasia type 1. Mol Cell Endocrinol. 2006;249:123-32.
34. Effraimidis G, Rasmussen ÅK, Dunoe M, et al. Systematic cascade screening in the Danish Fabry Disease Centre: 20 years of a national single-centre experience. PLoS One. 2022;17:e0277767.
35. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416-27.
36. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112-28.
37. Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.
38. Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Lund AM. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet. 2013;83:432-8.
39. Bengtsson BA, Johansson JO, Hollak C, Linthorst G, FeldtRasmussen U. Enzyme replacement in Anderson-Fabry disease. Lancet. 2003;361:352.
40. Arends M, Biegstraaten M, Wanner C, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55:351-8.
41. Wilcox WR, Linthorst GE, Germain DP, et al. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. Mol Genet Metab. 2012;105:443-9.
42. Lenders M, Brand E. Precision medicine in Fabry disease. Nephrol Dial Transplant. 2021;36:14-23.
43. Wanner C, Ortiz A, Wilcox WR, et al. Global reach of over 20 years of experience in the patient-centered Fabry Registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. Mol Genet Metab. 2023;139:107603.
44. Beck M, Ramaswami U, Hernberg-Ståhl E, et al. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2022;17:238.
45. Ramaswami U, Pintos-Morell G, Kampmann C, et al. Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy. Mol Genet Metab Rep. 2025;43:101215.
47. Schiffmann R, Bichet DG, Jovanovic A, et al. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet J Rare Dis. 2018;13:68.
48. Bichet DG, Torra R, Wallace E, et al. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease. Mol Genet Metab Rep. 2021;28:100786.
49. Hughes DA, Sunder-Plassmann G, Jovanovic A, et al. Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registry. J Inherit Metab Dis. 2025;48:e12771.
50. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375:545-55.
51. Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54:288-96.
52. Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020;131:219-28.
53. Hughes DA, Bichet DG, Giugliani R, et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes. J Med Genet. 2023;60:722-31.
54. Perretta F, Jaurretche S. Fabry disease: switch from enzyme replacement therapy to oral chaperone migalastat: what do we know today? Healthcare. 2023;11:449.
55. Holida M, Linhart A, Pisani A, et al. A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. J Inherit Metab Dis. 2025;48:e12795.
56. Fabrys sygdom. Available from: https://medicinraadet.dk/anbefalinger-og-vejledninger/behandlingsvejledninger-og-laegemiddelrekommandationer/fabrys-sygdom [Last accessed on 12 Sep 2025].
57. Jeyakumar JM, Kia A, Tam LCS, et al. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Gene Ther. 2023;30:487-502.
58. Rodríguez-Castejón J, Beraza-Millor M, Solinís MÁ, Rodríguez-Gascón A, Del Pozo-Rodríguez A. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review. Drug Deliv Transl Res. 2024;14:2615-28.
59. Lenders M, Menke ER, Brand E. Progress and challenges in the treatment of Fabry disease. BioDrugs. 2025;39:517-35.
60. der Veen SJ, Hollak CEM, van Kuilenburg ABP, Langeveld M. Developments in the treatment of Fabry disease. J Inherit Metab Dis. 2020;43:908-21.
61. Tsatsaronis A, Tiong M, Nicholls K, Ruderman I. Sodium-glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real-world case series. Intern Med J. 2025;55:617-21.
62. Ghanem CI, Pérez MJ, Manautou JE, Mottino AD. Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity. Pharmacol Res. 2016;109:119-31.
63. Leavitt VM, Tozlu C, Nelson KE, et al. A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis. J Neurol. 2024;271:2207-15.
64. Al-Chaer RN, Folkmann M, Mårtensson NL, Feldt-Rasmussen U, Mogensen M. Cutaneous manifestations of Fabry disease: a systematic review. J Dermatol. 2025;52:571-82.
65. Effraimidis G, Feldt-Rasmussen U, Rasmussen ÅK, et al. Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort. J Med Genet. 2021;58:692-700.
66. Madsen CV, Christensen EI, Nielsen R, Mogensen H, Rasmussen ÅK, Feldt-rasmussen U. Enzyme replacement therapy during pregnancy in Fabry patients: review of published cases of live Births and a new case of a severely affected female with Fabry Disease and pre-eclampsia complicating pregnancy. JIMD Rep. 2019;44:93-101.
67. Hespe S, Waddell A, Asatryan B, et al. Genes associated with hypertrophic cardiomyopathy: a reappraisal by the ClinGen hereditary cardiovascular disease gene curation expert panel. J Am Coll Cardiol. 2025;85:727-40.
68. Ramaswami U, West ML, Tylee K, et al. The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: a systematic literature review. Mol Genet Metab. 2025;145:109110.
69. Bichet DG, Aerts JM, Auray-Blais C, et al. Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease. Genet Med. 2021;23:192-201.
70. Effraimidis G, Rasmussen ÅK, Bundgaard H, Sørensen SS, Feldt-Rasmussen U. Is the alpha-galactosidase A variant p.Asp313Tyr
71. Hopkin RJ, Cabrera GH, Jefferies JL, et al. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry Registry. Mol Genet Metab. 2023;138:106967.
72. Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137:49-61.
73. Brand E, Linhart A, Deegan P, et al. Clinical management of female patients with Fabry disease based on expert consensus. Orphanet J Rare Dis. 2025;20:7.
74. Hughes DA, Aguiar P, Lidove O, et al. Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease? Orphanet J Rare Dis. 2022;17:42.
